When was MVRIX founded?

MVRIX was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is MVRIX located?

MVRIX is headquartered in Hwaseong si, South Korea.

Is MVRIX a funded company?

MVRIX is a funded company, having raised a total of $8.25M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2022.

When was the latest funding round of MVRIX?

MVRIX's latest funding was a $***** Series B round on Sep 04, 2026, with participation from 5 investors. Its primary sector is Infectious Diseases. In South Korea, the Infectious Diseases sector has seen $37.4M in funding in 2026 to date.

Where does MVRIX rank among its competitors?

MVRIX ranks 65th amongst 296 active competitors, of which 75 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was MVRIX, which secured $5.89M in Sep, 2026.

Who are the top competitors of MVRIX?

MVRIX's top competitors include Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma. Among them, MVRIX secured the most recent funding round in September, 2026.

MVRIX - 2026 Company Profile, Team, Funding & Competitors

MVRIX is a series B company based in Hwaseong si (South Korea), founded in 2021. It operates as a Developer of therapeutics for infectious diseases. MVRIX has raised $8.25M in funding. The company has 296 active competitors, including 75 funded and 75 that have exited. Its top competitors include companies like Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma.

Company Details

Developer of therapeutics for infectious diseases. It offers antibacterial therapeutics for multidrug-resistant bacteria based on cell membrane translocation mechanisms. it offers pipeline of drug candidtes which include MVR-V001 for covid-19, MVR-V002 for influenza, and MVR-CM001 for botulinum toxin. It also offers antibody-nanodisc complex which is an antiviral antibody activity boosting platform.

Website: www.mvrix.co.kr/
Email ID: *****@mvrix.co.kr
Phone Number: +82 **********

Key Metrics

Founded Year

2021

Location

Hwaseong si, South Korea

Stage

Series B

Total Funding

$8.25M in 2 rounds

Latest Funding Round

Series B, Sep 04, 2026, $*****

Investors

InterVest & 5 more

Ranked

65^th among 296 active competitors

Similar Companies

Tonix Pharma & 361 more

View MVRIX's full profile

MVRIX has raised a total funding of $8.25M over 2 rounds. Its first funding round was on 2022. Its latest funding round was a Series B round on Sep 04, 2026 for $*****. 5 investors participated in its latest round. MVRIX has 6 institutional investors.

Here is the list of recent funding rounds of MVRIX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2026	1045515	Series B	4962209	7190598	4102082	6916400
2022	5703	Series A	4166	6056	4994	6007

Access funding benchmarks and valuations. Sign up today!

View details of MVRIX's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MVRIX include Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma. Here is the list of Top 10 competitors of MVRIX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	67/100
2nd	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	65/100
3rd	Ascletis Pharma 2011, Hangzhou (China), Public	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	64/100
4th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	64/100
5th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, America’s Seed Fund ... & 3 others	62/100
6th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	61/100
7th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	61/100
8th	SAB Biotherapeutics 2014, Sioux Falls (United States), Public	Developer of immunotherapeutics to treat infectious and autoimmune diseases	$49M	Merck, SD Equity Partners & 5 others	60/100
9th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	60/100
10th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	59/100
65th	MVRIX 2021, Hwaseong si (South Korea), Series B	Developer of therapeutics for infectious diseases	$8.25M	InterVest, Korea Omega Investment Corp & 4 others	45/100